by Kevin Dooley, MD | Dec 18, 2019 | News and Information
Arimoclomol, an investigational drug currently in a Phase 2/3 trial for inclusion body myositis (IBM), has received Fast Track designation from the FDA for treatment of this disabling muscle disease. This designation is designed to shorten the time needed for the FDA... 
by Kevin Dooley, MD | Jun 20, 2019 | News and Information
Hall of Fame Night Randy Marks, who coached Villanova’s lacrosse team for 24 years, had the enormous pleasure of introducing his son, Brian, as he was inducted into the Villanova Athletics Hall of Fame last February. A former star athlete himself, Coach Marks was... 
by Kevin Dooley, MD | May 31, 2019 | News and Information
Our team of 30 bike riders will be cycling on June 8 in the Million Dollar Bike Ride, an annual rare disease fundraising event sponsored by the Orphan Disease Center at the University of Pennsylvania. This year, for the first time, we have a team representing... 
by Kevin Dooley, MD | Apr 22, 2019 | News and Information
Researchers at the Yale School of Medicine in New Haven, CT are looking for patients with inclusion body myositis (IBM) to participate in a study using Electrical Impedance Myography (EIM). The purpose of the study is to learn if EIM is useful for measuring the... 
by Kevin Dooley, MD | Mar 27, 2019 | News and Information
Regeneron Pharmaceuticals has confirmed the cancellation of its previously announced Phase 2 clinical trial for inclusion body myositis (IBM). Regeneron had planned to test two therapies in combination to treat this rare muscle disease, which causes gradually... 